Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Announces Grant of European Patent Covering Oral Mucosal Immunotherapy for Food Allergy
March 08, 2019 10:01 ET | Intrommune Therapeutics
New York, March 08, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Announces First Close of Series A Preferred Equity Financing and Successful Close of Crowdfunding Financing Campaign to Support New Peanut Allergy Treatment
November 08, 2018 16:44 ET | Intrommune Therapeutics
New York, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Completes Pre-IND Meeting With FDA on INT301 for Peanut Allergy
September 06, 2018 07:11 ET | Intrommune Therapeutics
New York, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Submits Pre-IND Meeting Request to the U.S. FDA for INT301, Its Peanut Allergy Oral Mucosal Immunotherapy Drug Candidate, During Food Allergy Awareness Week
May 15, 2018 12:00 ET | Intrommune Therapeutics
New York, May 15, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a NYC-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Announces Crowdfunding Financing Campaign to Support Food Allergy Treatment Research
May 09, 2018 10:36 ET | Intrommune Therapeutics
New York, May 09, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics is pleased to announce the launch of a crowdfunding campaign on the Netcapital platform. This campaign supports the next steps of...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics to Present at Eighth Annual BioNJ BioPartnering Conference
April 24, 2018 09:27 ET | Intrommune Therapeutics
New York, April 24, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, announced today that it...
intrommune_icon_500x500.png
Intrommune Therapeutics Announces Expansion of Advisory Board with Three Top Food Allergy Experts
June 14, 2016 07:30 ET | Intrommune Therapeutics
New York, June 14, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, today...
intrommune_icon_500x500.png
Intrommune Therapeutics to Present at 2016 BIO International Convention
June 06, 2016 07:55 ET | Intrommune Therapeutics
New York, June 06, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, today...
intrommune_icon_500x500.png
Intrommune Therapeutics Announces Positive Results of Proof-of-Concept study of Oral Mucosal Immunotherapy (OMIT) Platform for the Treatment of Allergies
April 25, 2016 09:08 ET | Intrommune Therapeutics
Patient-friendly platform treats allergies while a patient brushes their teeth Oral mucosal route of administration demonstrated to be efficacious No gastrointestinal side effects...
intrommune_icon_500x500.png
Intrommune Therapeutics Announces Issuance of U.S. Patent Covering Oral Mucosal Immunotherapy for Food Allergy
March 01, 2016 07:10 ET | Intrommune Therapeutics
New York, March 01, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, announced...